Table 4 Changes from baseline in ADAS-cog for each quintile TTP488 concentration range over 18 months of treatment
From: Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Month | Placebo | 0.1-10.2 ng/mL | 10.3-16.8 ng/mL | 17.0-46.3 ng/mL | 46.8-71.7 ng/mL | 75-167 ng/mL |
|---|---|---|---|---|---|---|
3 | 1.59 (0.43) | 0.83 (0.75) | 1.35 (0.74) | 2.51 (0.77) | 4.42 (0.84) | 7.4 (0.94) |
n = 129 | n = 50 | n = 51 | n = 52 | n = 47 | n = 48 | |
6 | 3.14 (0.54) | 2.24 (0.85) | 2.3 (0.87) | 4 (0.88) | 4.7 (0.82) | 9.1 (1) |
n = 115 | n = 48 | n = 49 | n = 48 | n = 37 | n = 46 | |
9 | 4.3 (0.7) | 1.9 (0.9) | 3 (0.93) | 4.3(1.1) | 5.1 (1.45) | 8.4 (1.3) |
n = 112 | n = 39 | n = 46 | n = 42 | n = 27 | n = 40 | |
12 | 6.4 (0.68) | 3 (0.76) | 5.6 (1.22) | 6.7 (1.3) | 7.4 (1.67) | 9.3 (1.3) |
n = 105 | n = 32 | n = 42 | n = 37 | n = 22 | n = 31 | |
15 | 9.9 (0.9) | 6.8 (0.98) | 6.9 (1.42) | 8.1 (0.4) | 9.3 (1.97) | 10.1 (1.9) |
n = 89 | n = 30 | n = 37 | n = 30 | n = 21 | n = 24 | |
18 | 11.9 (1.1) | 8.7 (1.36) | 8.1 (1.71) | 10.1 (2) | 10.1 (2.47) | 11.3(1.8) |
n = 64 | n = 25 | n = 26 | n = 25 | n = 15 | n = 19 |